Literature DB >> 32341577

Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome.

Jerzy Michal Dziekan1, Grennady Wirjanata1, Lingyun Dai1,2, Ka Diam Go1, Han Yu1, Yan Ting Lim3,4, Liyan Chen3,4, Loo Chien Wang3,4, Brenda Puspita1, Nayana Prabhu1, Radoslaw M Sobota5,6, Pär Nordlund7,8,9, Zbynek Bozdech10.   

Abstract

Despite decades of research, little is known about the cellular targets and the mode of action of the vast majority of antimalarial drugs. We recently demonstrated that the cellular thermal shift assay (CETSA) protocol in its two variants: the melt curve and the isothermal dose-response, represents a comprehensive strategy for the identification of antimalarial drug targets. CETSA enables proteome-wide target screening for unmodified antimalarial compounds with undetermined mechanisms of action, providing quantitative evidence about direct drug-protein interactions. The experimental workflow involves treatment of P. falciparum-infected erythrocytes with a compound of interest, heat exposure to denature proteins, soluble protein isolation, enzymatic digestion, peptide labeling with tandem mass tags, offline fractionation, and liquid chromatography-tandem mass spectrometry analysis. Methodological optimizations necessary for the analysis of this intracellular parasite are discussed, including enrichment of parasitized cells and hemoglobin depletion strategies to overcome high hemoglobin abundance in the host red blood cells. We outline an effective data processing workflow using the mineCETSA R package, which enables prioritization of drug-target candidates for follow-up studies. The entire protocol can be completed within 2 weeks.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32341577     DOI: 10.1038/s41596-020-0310-z

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  14 in total

1.  Temporal and thermal profiling of the Toxoplasma proteome implicates parasite Protein Phosphatase 1 in the regulation of Ca2+-responsive pathways.

Authors:  Alice L Herneisen; Zhu-Hong Li; Alex W Chan; Silvia N J Moreno; Sebastian Lourido
Journal:  Elife       Date:  2022-08-17       Impact factor: 8.713

2.  Thermal Proteome Profiling to Identify Protein-ligand Interactions in the Apicomplexan Parasite Toxoplasma gondii.

Authors:  Alice L Herneisen; Sebastian Lourido
Journal:  Bio Protoc       Date:  2021-11-05

Review 3.  Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials.

Authors:  Maëlle Duffey; Benjamin Blasco; Jeremy N Burrows; Timothy N C Wells; David A Fidock; Didier Leroy
Journal:  Trends Parasitol       Date:  2021-05-14

Review 4.  Chemoproteomics for Plasmodium Parasite Drug Target Discovery.

Authors:  Kuan-Yi Lu; Christopher R Mansfield; Michael C Fitzgerald; Emily R Derbyshire
Journal:  Chembiochem       Date:  2021-06-10       Impact factor: 3.461

Review 5.  The antimalarial resistome - finding new drug targets and their modes of action.

Authors:  Krypton Carolino; Elizabeth A Winzeler
Journal:  Curr Opin Microbiol       Date:  2020-07-15       Impact factor: 7.934

6.  1-Formyl-β-carboline Derivatives Block Newcastle Disease Virus Proliferation through Suppressing Viral Adsorption and Entry Processes.

Authors:  Chongyang Wang; Ting Wang; Jiangkun Dai; Zhiyuan An; Ruochen Hu; Liuyuan Duan; Hui Chen; Xiangwei Wang; Zhili Chu; Haijin Liu; Juan Wang; Na Li; Zengqi Yang; Junru Wang
Journal:  Biomolecules       Date:  2021-11-12

Review 7.  An update of label-free protein target identification methods for natural active products.

Authors:  Zhao Cui; Caifeng Li; Peng Chen; Hongjun Yang
Journal:  Theranostics       Date:  2022-01-24       Impact factor: 11.556

8.  A Bayesian semi-parametric model for thermal proteome profiling.

Authors:  Siqi Fang; Paul D W Kirk; Marcus Bantscheff; Kathryn S Lilley; Oliver M Crook
Journal:  Commun Biol       Date:  2021-06-29

9.  Identification of Proteomic Signatures in Chronic Obstructive Pulmonary Disease Emphysematous Phenotype.

Authors:  Shuang Bai; Rui Ye; Cuihong Wang; Pengbo Sun; Di Wang; Yong Yue; Huiying Wang; Si Wu; Miao Yu; Shuhua Xi; Li Zhao
Journal:  Front Mol Biosci       Date:  2021-07-01

10.  CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.

Authors:  Tomas Friman; Alexey Chernobrovkin; Daniel Martinez Molina; Laurence Arnold
Journal:  SLAS Discov       Date:  2020-11-18       Impact factor: 3.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.